Literature DB >> 17085671

Synthetic microRNA designed to target glioma-associated antigen 1 transcription factor inhibits division and induces late apoptosis in pancreatic tumor cells.

Naotake Tsuda1, Satoshi Ishiyama, Yufeng Li, Constantin G Ioannides, James L Abbruzzese, David Z Chang.   

Abstract

PURPOSE: To determine whether the synthetic microRNAs (miRNA) could effectively target tumor cells we designed several miRNA complementary to glioma-associated antigen-1 (Gli-1) mRNA and investigated their ability to inhibit tumor cell proliferation. The sonic hedgehog pathway is an early and late mediator of tumorigenesis in epithelial cancers. Activation of sonic hedgehog signaling seems to precede transformation of tissue stem cells to cancerous stem cells, with the Gli-1 transcription factor functioning as a mediator of environmental signals. Inhibiting cancer cell proliferation by targeting the Gli-1 effector pathway is difficult to achieve by chemotherapeutic agents or short interfering RNA. EXPERIMENTAL
DESIGN: We hypothesized that targeting the 3'-untranslated region of Gli-1 mRNA would effectively inhibit tumor cell proliferation. To test this hypothesis, we used synthetic miRNAs of our own design and corresponding duplex/small temporal RNAs by introducing three-nucleotide loops in the 3'-untranslated region Gli-1 sequence of high GU content.
RESULTS: We found that miRNA (Gli-1-miRNA-3548) and its corresponding duplex (Duplex-3548) significantly inhibited proliferation of Gli-1+ ovarian (SK-OV-3) and pancreatic (MiaPaCa-2) tumor cells. The miRNAs mediated delayed cell division and activation of late apoptosis in MiaPaCa-2 cells. This is the first demonstration of inhibition of pancreatic tumor cell division by designed miRNA.
CONCLUSIONS: Gli-1 miRNAs should significantly add to the general understanding of the mechanisms of metastasis and contribute toward the design of better treatments for epithelial cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17085671     DOI: 10.1158/1078-0432.CCR-06-0588

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  38 in total

1.  MicroRNA signatures of stem cells.

Authors:  Dipak K Das; Partha Mukhopadhyay
Journal:  Exp Clin Cardiol       Date:  2011

2.  MicroRNA-based Cancer Therapeutics: Big Hope from Small RNAs.

Authors:  Arun Bhardwaj; Seema Singh; Ajay P Singh
Journal:  Mol Cell Pharmacol       Date:  2010

Review 3.  MicroRNAs and cardiac pathology.

Authors:  Michael V G Latronico; Gianluigi Condorelli
Journal:  Nat Rev Cardiol       Date:  2009-06       Impact factor: 32.419

Review 4.  Regulating miRNA by natural agents as a new strategy for cancer treatment.

Authors:  Sajiv Sethi; Yiwei Li; Fazlul H Sarkar
Journal:  Curr Drug Targets       Date:  2013-09       Impact factor: 3.465

Review 5.  MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications.

Authors:  Satyanarayana Rachagani; Sushil Kumar; Surinder K Batra
Journal:  Cancer Lett       Date:  2009-12-09       Impact factor: 8.679

Review 6.  Molecular discoveries and treatment strategies by direct reprogramming in cardiac regeneration.

Authors:  John H Werner; John H Rosenberg; John Y Um; Michael J Moulton; Devendra K Agrawal
Journal:  Transl Res       Date:  2018-07-31       Impact factor: 7.012

7.  Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy.

Authors:  Mohammad Aslam Khan; Haseeb Zubair; Sanjeev Kumar Srivastava; Seema Singh; Ajay Pratap Singh
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

Review 8.  Sequence-non-specific effects of RNA interference triggers and microRNA regulators.

Authors:  Marta Olejniczak; Paulina Galka; Wlodzimierz J Krzyzosiak
Journal:  Nucleic Acids Res       Date:  2009-10-20       Impact factor: 16.971

9.  Non-coding RNAs: a key to future personalized molecular therapy?

Authors:  Marco Galasso; Maria Elena Sana; Stefano Volinia
Journal:  Genome Med       Date:  2010-02-18       Impact factor: 11.117

10.  Smoothened as a new therapeutic target for human osteosarcoma.

Authors:  Masataka Hirotsu; Takao Setoguchi; Hiromi Sasaki; Yukihiro Matsunoshita; Hui Gao; Hiroko Nagao; Osamu Kunigou; Setsuro Komiya
Journal:  Mol Cancer       Date:  2010-01-12       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.